Complete patient dosing for Part 1 of Gene Therapy Trial in Friedreich Ataxia Cardiomyopathy.

Published Date: 23 Jul 2023

The 52-week, dose-ascending trial's data will be read out in the first half of 2024, and after the initial trial is over, long-term safety and efficacy will be assessed over a 5-year period.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Scientists hail the cervical cancer treatment as the most remarkable breakthrough in 20 years.

2.

Researchers use AI to monitor side effects of chemotherapy and support families dealing with pediatric cancer.

3.

Study finds 20 minutes of mindful breathing can rapidly reduce intensity of cancer pain

4.

Report suggests a big improvement in lung cancer survival

5.

The clinical trial of ENZAMET shows promise as a treatment for prostate cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot